Methyllactam ring compound and pharmaceutical use thereof
An object of the present invention is to provide a methyllactam ring compound that has an SGLT1 inhibitory activity and is useful for a drug, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof. A compound of Formula [I]: or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof is provided.
1. A compound of Formula [I]:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
3. A method for inhibiting SGLT1 comprising administering a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof to a mammal.
4. A method for treating diabetes comprising administering a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof to a mammal.
5. The method according to claim 4 , wherein the diabetes is type 2 diabetes.
6. A compound of Formula [I]:
7. A pharmaceutical composition comprising the compound according to claim 6 and a pharmaceutically acceptable carrier.
8. A method for inhibiting SGLT1 comprising administering a therapeutically effective amount of the compound according to claim 6 to a mammal.
9. A method for treating diabetes comprising administering a therapeutically effective amount of the compound according to claim 6 to a mammal.
10. The method according to claim 9 , wherein the diabetes is type 2 diabetes.